Cargando…
Pharmacological hypothesis: A recombinant probiotic for taming bacterial β‐glucuronidase in drug‐induced enteropathy
Advances in pharmacomicrobiomics have shed light on the pathophysiology of drug‐induced enteropathy associated with the therapeutic use of certain non‐steroidal anti‐inflammatory drugs, anticancer chemotherapies and immunosuppressants. The toxicity pathway results from the post‐glucuronidation relea...
Autores principales: | Jardou, Manon, Brossier, Clarisse, Guiyedi, Kenza, Faucher, Quentin, Lawson, Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9460963/ https://www.ncbi.nlm.nih.gov/pubmed/36082825 http://dx.doi.org/10.1002/prp2.998 |
Ejemplares similares
-
Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model
por: Jardou, Manon, et al.
Publicado: (2021) -
Is Intestinal Dysbiosis-Associated With Immunosuppressive Therapy a Key Factor in the Pathophysiology of Post-Transplant Diabetes Mellitus?
por: Faucher, Quentin, et al.
Publicado: (2022) -
The Origin of Urinary β-Glucuronidase
por: Fripp, P. J.
Publicado: (1965) -
Supportive therapy during COVID-19: The proposed mechanism of short-chain fatty acids to prevent cytokine storm and multi-organ failure
por: Jardou, M., et al.
Publicado: (2021) -
Taming beams
Publicado: (1972)